Incontinence Drug Utilization Patterns in Québec, Canada

Value in Health

Volumn 2, Issue 6, 1999, Pages 452-458

  Desgagné, Alain ^a   LeLorier, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003179082     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1999.26005.x     Document Type: Article

References (23)

1. O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence: quality of life and patient's valuation of symptom reduction. Pharmacoeconomics 1998;14:531-9.
2. Wyman JF. The psychiatric and emotional impact of female pelvic floor dysfunction. Curr Opin Obstet Gynaecol 1994;6:336-9.
3. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics and study type. J Am Geriatr Soc 1998;46:473-80.
4. National Institutes of Health Consensus Development Conference on Urinary Incontinence in Adults. Proceedings, Bethesda, Maryland, October 3-5, 1998. J Am Geriatr Soc 1990;38:263-386.
5. Hu T-W. Impact of urinary incontinence on healthcare costs. J Am Geriatr Soc 1990;38:292-5.
6. Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalisation, nursing home admission and mortality. Age & Aging 1997;26:367-74.
7. Callahan CM. The costs of urinary incontinence. Pharmacoeconomics 1994;6:183-5.
8. Wagner TH, Hu T-W. Economic costs of urinary incontinence in 1995. Urology 1998;51:355-61.
9. Busby-Whitehead J, Johnson TM. Urinary incontinence. Clin Geriatr Med 1998;14:285-96.
10. Sourander LB. Treatment of urinary incontinence: the place of drugs. Gerontology 1990;36(Suppl. 2):19-26.
11. Wein AJ. Pharmacologic options for the overactive bladder. Urology 1998;51(Suppl. 2A):43-7.
12. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs & Aging 1995;6:243-62.
13. Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age & Ageing 1995;24:287-91.
14. Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991;145:813-7.
15. Donnellan CA, Fook L, McDonald P, Playfer JR. Oxybutynin and cognitive dysfunction. BMJ 1997;315:1363-4.
16. Chapple CR, Parkhouse H, Gardener C, Milroy EJG. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Br J Urol 1990;66:491-4.
17. Urinary Incontinence in adults. Acute and chronic management. Clin Prac Guidelines Number, 1996;2 (1996: Update). Agency for Health Care Policy and Research, Publication no. 96-0682: March.
18. Government of Québec. Régie l'assurance-maladie Québec. Liste de médicaments. 1996;46:213.
19. Baigrie RJ, Kelleher JP, Fawcett DP, Pengelly AW. Oxybutynin: is it safe? Br J Urol 1988;62:319-22.
20. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
21. Tapp AJS, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990;97:521-6.
22. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims database in pharmacoepidemiology research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
23. Jackson S. The patient with an overactive bladder - symptoms and quality-of-life issues. Urology 1997;50 (Suppl6A):18-22.